التفاصيل البيبلوغرافية
| العنوان: |
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements. |
| المؤلفون: |
Martínez-Pérez, Alejandra, Granda-Díaz, Rocío, Aguilar-García, Candelaria, Sordo-Bahamonde, Christian, Gonzalez, Segundo |
| المصدر: |
Biomarker Research; 10/18/2024, Vol. 12 Issue 1, p1-13, 13p |
| مصطلحات موضوعية: |
IMMUNE checkpoint proteins, CANCER treatment, TREATMENT effectiveness, CYTOTOXIC T lymphocyte-associated molecule-4, PROGRAMMED cell death 1 receptors |
| مستخلص: |
Treatment based on immune checkpoint blockade has revolutionized cancer therapy. Despite the remarkable success achieved and the preclinical development of multiple checkpoint inhibitors targeting other checkpoints, only antibodies targeting the PD-1/PD-L1 axis and CTLA-4 have been approved for patient treatment, especially in solid tumors. Currently, with the approval of relatlimab, a LAG-3 blocking antibody, a third player, has been used in the fight against cancer. The endorsement of relatlimab marks a significant milestone in cancer immunotherapy, opening new avenues for combination therapies and enhancing treatment outcomes. However, the complex biology of LAG-3 may hinder its full development as a therapeutic alternative. In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Biomarker Research is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder